Trade PharmaCyte Biotech, Inc. - PMCB CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
| Spread | 0.06 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026151% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003929% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
| Prev. Close* | 2.16 |
| Open* | 2.13 |
| 1-Year Change* | -14.8% |
| Day's Range* | 2.06 - 2.15 |
| 52 wk Range | 2.30-3.23 |
| Average Volume (10 days) | 16.33K |
| Average Volume (3 months) | 561.04K |
| Market Cap | 20.54M |
| P/E Ratio | -100.00K |
| Shares Outstanding | 8.78M |
| Revenue | N/A |
| EPS | -0.21 |
| Dividend (Yield %) | N/A |
| Beta | -0.01 |
| Next Earnings Date | Sep 25, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Sep 26, 2023 | 2.15 | 0.02 | 0.94% | 2.13 | 2.15 | 2.06 |
| Sep 25, 2023 | 2.16 | -0.08 | -3.57% | 2.24 | 2.24 | 2.16 |
| Sep 22, 2023 | 2.31 | -0.01 | -0.43% | 2.32 | 2.33 | 2.22 |
| Sep 21, 2023 | 2.28 | -0.06 | -2.56% | 2.34 | 2.34 | 2.28 |
| Sep 20, 2023 | 2.32 | 0.00 | 0.00% | 2.32 | 2.38 | 2.29 |
| Sep 19, 2023 | 2.44 | 0.07 | 2.95% | 2.37 | 2.50 | 2.37 |
| Sep 18, 2023 | 2.52 | 0.07 | 2.86% | 2.45 | 2.52 | 2.32 |
| Sep 15, 2023 | 2.46 | 0.05 | 2.07% | 2.41 | 2.49 | 2.40 |
| Sep 14, 2023 | 2.56 | 0.12 | 4.92% | 2.44 | 2.58 | 2.44 |
| Sep 13, 2023 | 2.45 | 0.03 | 1.24% | 2.42 | 2.46 | 2.34 |
| Sep 12, 2023 | 2.41 | 0.05 | 2.12% | 2.36 | 2.43 | 2.33 |
| Sep 11, 2023 | 2.44 | 0.00 | 0.00% | 2.44 | 2.45 | 2.40 |
| Sep 8, 2023 | 2.44 | 0.12 | 5.17% | 2.32 | 2.46 | 2.32 |
| Sep 7, 2023 | 2.32 | -0.01 | -0.43% | 2.33 | 2.37 | 2.28 |
| Sep 6, 2023 | 2.35 | 0.03 | 1.29% | 2.32 | 2.39 | 2.32 |
| Sep 5, 2023 | 2.38 | -0.05 | -2.06% | 2.43 | 2.45 | 2.36 |
| Sep 1, 2023 | 2.46 | 0.01 | 0.41% | 2.45 | 2.46 | 2.38 |
| Aug 31, 2023 | 2.43 | 0.04 | 1.67% | 2.39 | 2.44 | 2.35 |
| Aug 30, 2023 | 2.42 | 0.04 | 1.68% | 2.38 | 2.43 | 2.34 |
| Aug 29, 2023 | 2.42 | 0.08 | 3.42% | 2.34 | 2.44 | 2.33 |
PharmaCyte Biotech, Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| Monday, December 11, 2023 | ||
| Time (UTC) 21:00 | Country US
| Event Q2 2024 PharmaCyte Biotech Inc Earnings Release Q2 2024 PharmaCyte Biotech Inc Earnings ReleaseForecast -Previous - |
| Thursday, December 28, 2023 | ||
| Time (UTC) 15:00 | Country US
| Event PharmaCyte Biotech Inc Annual Shareholders Meeting PharmaCyte Biotech Inc Annual Shareholders MeetingForecast -Previous - |
- Annual
- Quarterly
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 |
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue, Total | |||||
| Gross Profit | |||||
| Total Operating Expense | 6.45549 | 4.39201 | 3.547 | 3.8264 | 4.10063 |
| Selling/General/Admin. Expenses, Total | 5.98696 | 3.70108 | 2.70673 | 3.52517 | 3.64058 |
| Research & Development | 0.46854 | 0.69094 | 0.91625 | 0.30122 | 0.46005 |
| Unusual Expense (Income) | 0 | -0.07598 | |||
| Operating Income | -6.45549 | -4.39201 | -3.547 | -3.8264 | -4.10063 |
| Interest Income (Expense), Net Non-Operating | 1.9375 | 0.15714 | -0.00305 | -0.00045 | |
| Other, Net | 0.202 | -0.00428 | -0.00119 | -0.00004 | 0.0334 |
| Net Income Before Taxes | -4.31599 | -4.23916 | -3.55124 | -3.82689 | -4.06723 |
| Net Income After Taxes | -4.31599 | -4.23916 | -3.55124 | -3.82689 | -4.06723 |
| Net Income Before Extra. Items | -4.31599 | -4.23916 | -3.55124 | -3.82689 | -4.06723 |
| Net Income | -4.31599 | -4.23916 | -3.55124 | -3.82689 | -4.06723 |
| Income Available to Common Excl. Extra. Items | -4.31599 | -4.23916 | -3.55124 | -3.82689 | -4.06723 |
| Income Available to Common Incl. Extra. Items | -4.31599 | -4.23916 | -3.55124 | -3.82689 | -4.06723 |
| Diluted Net Income | -4.31599 | -4.23916 | -3.55124 | -3.82689 | -4.06723 |
| Diluted Weighted Average Shares | 19.4892 | 15.5217 | 1.44829 | 0.90833 | 0.73707 |
| Diluted EPS Excluding Extraordinary Items | -0.22146 | -0.27311 | -2.45203 | -4.2131 | -5.5181 |
| Dividends per Share - Common Stock Primary Issue | |||||
| Diluted Normalized EPS | -0.22146 | -0.27311 | -2.50449 | -4.2131 | -5.5181 |
| Total Extraordinary Items |
| Apr 2023 | Jan 2023 | Oct 2022 | Jul 2022 | Apr 2022 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 |
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Total Operating Expense | 0.90328 | 1.55298 | 2.31862 | 1.68061 | 1.5077 |
| Selling/General/Admin. Expenses, Total | 0.81741 | 1.50759 | 2.14062 | 1.52134 | 1.25364 |
| Research & Development | 0.08587 | 0.04539 | 0.178 | 0.15927 | 0.25407 |
| Operating Income | -0.90328 | -1.55298 | -2.31862 | -1.68061 | -1.5077 |
| Interest Income (Expense), Net Non-Operating | 0.72294 | 0.63589 | 0.43917 | 0.1395 | 0.08657 |
| Other, Net | 0.05401 | 0.15296 | -0.00106 | -0.00391 | -0.00157 |
| Net Income Before Taxes | -0.12634 | -0.76414 | -1.88051 | -1.54501 | -1.42271 |
| Net Income After Taxes | -0.12634 | -0.76414 | -1.88051 | -1.54501 | -1.42271 |
| Net Income Before Extra. Items | -0.12634 | -0.76414 | -1.88051 | -1.54501 | -1.42271 |
| Net Income | -0.12634 | -0.76414 | -1.88051 | -1.54501 | -1.42271 |
| Income Available to Common Excl. Extra. Items | -0.12634 | -0.76414 | -1.88051 | -1.54501 | -1.42271 |
| Income Available to Common Incl. Extra. Items | -0.12634 | -0.76414 | -1.88051 | -1.54501 | -1.42271 |
| Diluted Net Income | -0.12634 | -0.76414 | -1.88051 | -1.54501 | -1.42271 |
| Diluted Weighted Average Shares | 17.802 | 18.9954 | 20.5854 | 20.8293 | 21.4702 |
| Diluted EPS Excluding Extraordinary Items | -0.0071 | -0.04023 | -0.09135 | -0.07417 | -0.06626 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | ||
| Diluted Normalized EPS | -0.0071 | -0.04023 | -0.09135 | -0.07417 | -0.06626 |
| Unusual Expense (Income) | 0 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total Current Assets | 85.4948 | 2.27524 | 1.03765 | 0.6534 | 1.28387 |
| Cash and Short Term Investments | 85.4007 | 2.20211 | 0.89486 | 0.51525 | 1.0598 |
| Cash | 85.4007 | 2.20211 | 0.89486 | 0.51525 | 1.0598 |
| Prepaid Expenses | 0.09417 | 0.07313 | 0.14279 | 0.13815 | 0.22407 |
| Total Assets | 90.6241 | 7.40423 | 6.16664 | 5.7824 | 6.41286 |
| Intangibles, Net | 3.54943 | 3.54943 | 3.54943 | 3.54943 | 3.54943 |
| Long Term Investments | 1.57219 | 1.57219 | 1.57219 | 1.57219 | 1.57219 |
| Other Long Term Assets, Total | 0.00769 | 0.00737 | 0.00737 | 0.00737 | 0.00737 |
| Total Current Liabilities | 0.70437 | 0.72478 | 1.0314 | 0.74285 | 0.64417 |
| Accounts Payable | 0.20536 | 0.17226 | 0.18584 | 0.12189 | 0.35262 |
| Accrued Expenses | 0.49901 | 0.55252 | 0.81664 | 0.62097 | 0.29155 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | |||||
| Total Liabilities | 0.70437 | 0.72478 | 1.07768 | 0.74285 | 0.64417 |
| Total Long Term Debt | 0 | 0 | 0.04628 | 0 | 0 |
| Total Equity | 89.9198 | 6.67945 | 5.08896 | 5.03955 | 5.76869 |
| Common Stock | 0.00207 | 0.00016 | 0.16386 | 0.1186 | 0.10133 |
| Additional Paid-In Capital | 201.582 | 114.109 | 108.805 | 104.966 | 101.636 |
| Retained Earnings (Accumulated Deficit) | -111.649 | -107.41 | -103.858 | -100.031 | -95.9641 |
| Other Equity, Total | -0.01576 | -0.02038 | -0.02171 | -0.01384 | -0.00471 |
| Total Liabilities & Shareholders’ Equity | 90.6241 | 7.40423 | 6.16664 | 5.7824 | 6.41286 |
| Total Common Shares Outstanding | 20.7211 | 1.59008 | 1.09789 | 0.79462 | 0.67888 |
| Current Port. of LT Debt/Capital Leases | 0 | 0.02892 | |||
| Long Term Debt | 0 | 0.04628 |
| Jan 2023 | Oct 2022 | Jul 2022 | Apr 2022 | Jan 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 72.8212 | 77.2194 | 82.2558 | 85.4948 | 86.8139 |
| Cash and Short Term Investments | 72.6402 | 76.9626 | 82.2276 | 85.4007 | 86.6398 |
| Cash | 72.6402 | 76.9626 | 82.2276 | 85.4007 | 86.6398 |
| Prepaid Expenses | 0.18101 | 0.25681 | 0.02815 | 0.09417 | 0.1741 |
| Total Assets | 77.9505 | 82.3487 | 87.3851 | 90.6241 | 91.9432 |
| Intangibles, Net | 3.54943 | 3.54943 | 3.54943 | 3.54943 | 3.54943 |
| Long Term Investments | 1.57219 | 1.57219 | 1.57219 | 1.57219 | 1.57219 |
| Other Long Term Assets, Total | 0.00769 | 0.00769 | 0.00769 | 0.00769 | 0.00769 |
| Total Current Liabilities | 0.82783 | 1.31113 | 1.08936 | 0.70437 | 0.61298 |
| Accounts Payable | 0.44594 | 0.86128 | 0.55903 | 0.20536 | 0.09286 |
| Accrued Expenses | 0.3819 | 0.44986 | 0.53033 | 0.49901 | 0.52012 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | |||||
| Total Liabilities | 0.82783 | 1.31113 | 1.08936 | 0.70437 | 0.61298 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Long Term Debt | |||||
| Total Equity | 77.1227 | 81.0376 | 86.2957 | 89.9198 | 91.3302 |
| Common Stock | 0.00216 | 0.00216 | 0.00216 | 0.00207 | 0.00207 |
| Additional Paid-In Capital | 202.231 | 201.601 | 201.593 | 201.582 | 201.573 |
| Retained Earnings (Accumulated Deficit) | -115.838 | -115.074 | -113.194 | -111.649 | -110.226 |
| Other Equity, Total | -0.01773 | -0.01517 | -0.01445 | -0.01576 | -0.0193 |
| Total Liabilities & Shareholders’ Equity | 77.9505 | 82.3487 | 87.3851 | 90.6241 | 91.9432 |
| Total Common Shares Outstanding | 18.209 | 20.7211 | 20.7501 | 20.7211 | 20.7202 |
| Treasury Stock - Common | -9.25401 | -5.47589 | -2.09085 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -4.23916 | -3.55124 | -3.82689 | -4.06723 | -6.82884 |
| Cash From Operating Activities | -4.11732 | -3.33089 | -2.33837 | -2.87791 | -5.0794 |
| Non-Cash Items | 0.1128 | 0.36596 | 1.22117 | 1.02222 | 1.83532 |
| Cash Interest Paid | 0.00051 | 0.00227 | 0.00045 | ||
| Changes in Working Capital | 0.00904 | -0.14561 | 0.26735 | 0.1671 | -0.08587 |
| Cash From Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Other Investing Cash Flow Items, Total | 0 | 0 | 0 | 0 | 0 |
| Cash From Financing Activities | 87.3112 | 4.63681 | 2.72585 | 2.3425 | 2.68141 |
| Issuance (Retirement) of Stock, Net | 87.3621 | 4.69925 | 2.663 | 2.3425 | 2.68141 |
| Issuance (Retirement) of Debt, Net | -0.05081 | -0.06244 | 0.06285 | ||
| Foreign Exchange Effects | 0.00463 | 0.00133 | -0.00787 | -0.00913 | -0.00645 |
| Net Change in Cash | 83.1985 | 1.30725 | 0.37961 | -0.54455 | -2.40443 |
| Cash Taxes Paid | 0.0016 | 0.0008 | 0.0008 |
| Jan 2023 | Oct 2022 | Jul 2022 | Apr 2022 | Jan 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -4.18966 | -3.42552 | -1.54501 | -4.23916 | -2.81645 |
| Cash From Operating Activities | -3.50534 | -2.96364 | -1.08438 | -4.11732 | -2.92548 |
| Non-Cash Items | 0.81355 | 0.01775 | 0.00962 | 0.1128 | 0.10406 |
| Cash Taxes Paid | 0 | 0 | 0 | 0.0016 | 0.0016 |
| Cash Interest Paid | 0 | 0 | 0 | 0.00051 | 0.00051 |
| Changes in Working Capital | -0.12924 | 0.44413 | 0.45101 | 0.00904 | -0.21309 |
| Cash From Investing Activities | 0 | 0 | 0 | 0 | |
| Other Investing Cash Flow Items, Total | 0 | 0 | 0 | 0 | |
| Cash From Financing Activities | -9.25313 | -5.47501 | -2.08997 | 87.3112 | 87.3621 |
| Issuance (Retirement) of Stock, Net | -9.25313 | -5.47501 | -2.08997 | 87.3621 | 87.3621 |
| Issuance (Retirement) of Debt, Net | -0.05081 | 0 | |||
| Foreign Exchange Effects | -0.00197 | 0.00058 | 0.0013 | 0.00463 | 0.00108 |
| Net Change in Cash | -12.7604 | -8.43807 | -3.17304 | 83.1985 | 84.4377 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
PharmaCyte Biotech, Inc. Company profile
About Pharmacyte Biotech Inc
PharmaCyte Biotech, Inc. is a clinical-stage biotechnology company. The Company is focused on developing cellular therapies for cancer and diabetes based upon a cellulose-based live cell encapsulation technology known as Cell-in-a-Box. Cell-in-a-Box technology is used as a platform upon which therapies for several types of cancer, including locally advanced, inoperable, non-metastatic pancreatic cancer (LAPC). The Company's lead product candidate, CypCaps is in Phase II of the clinical trials in LAPC. It also focused on developing a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes. Its product candidate for the treatment of diabetes consists of encapsulated genetically modified insulin-producing cells. The Company is also focused on the benefits of the Cell-in-a-Box technology to develop therapies for cancer that involve prodrugs based upon certain constituents of the Cannabis plant, such as cannabinoids.
Financial summary
BRIEF: For the nine months ended 31 January 2022, Pharmacyte Biotech Inc revenues was not reported. Net loss increased 9% to $2.8M. Higher net loss reflects General and administrative increase from $291K to $836K (expense), Legal and professional increase of 85% to $601K (expense), Director fees increase of 1% to $209K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$1.88 to -$0.74.
Equity composition
Common Stock $0.0001 Par, 03/11, 500M auth., 353,387,581 issd. Insiders own 9.09%. 12/03, 3 for 1 forward stock split. 03/09, Name changed from eFoodSafety.com Inc. Preferred Stock $.0001 Par, 10M auth., 5K issd.
| Industry: | Pharmaceuticals (NEC) |
3960 Howard Hughes Parkway, Suite 500
LAS VEGAS
NEVADA 89169
US
Income Statement
- Annual
- Quarterly
News
Q4 lookahead: US indices starting to show signs of trouble?
US indices start to draw attention as traders focus on the outlook for Q4.
07:20, 27 September 2023
USD/JPY Climbs Towards Key Highs
USDJPY’s powerful long-term uptrend has been reignited after last week’s sharply contrasting policy statements from the Federal Reserve and Bank of Japan.
11:32, 26 September 2023
EUR/USD tests key support
EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.
14:32, 21 September 2023
BoE leaves rates unchanged, GBP drops further as investors look for more clarity
The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August
11:45, 21 September 2023
GBP softer after CPI surprise, JPY focused on any further hints from Ueda
GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.
12:42, 20 September 2023
How to Trade The Break & Retest
In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.
11:59, 20 September 2023
Cable coils near lows ahead of Fed and BoE rate decisions
It’s a big week for Cable (GBP/USD) as both the Federal Reserve and the Bank of England are set to make crucial rate decisions.
14:16, 19 September 2023People also watch
Still looking for a broker you can trust?
Join the 555.000+ traders worldwide that chose to trade with Capital.com